WuXi Biologics (Cayman) Inc.

SEHK:2269 株式レポート

時価総額:HK$47.9b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

WuXi Biologics (Cayman) マネジメント

マネジメント 基準チェック /14

WuXi Biologics (Cayman)'sの CEO はChris Chenで、 Jan2016年に任命され、 の在任期間は 8.42年です。 の年間総報酬はCN¥ 96.91Mで、 4.1%給与と95.9%のボーナス(会社の株式とオプションを含む)で構成されています。 は、会社の株式の0.32%を直接所有しており、その価値はHK$ 165.39M 。経営陣と取締役会の平均在任期間はそれぞれ1.8年と6.8年です。

主要情報

Chris Chen

最高経営責任者

CN¥96.9m

報酬総額

CEO給与比率4.1%
CEO在任期間8.4yrs
CEOの所有権0.3%
経営陣の平均在職期間1.8yrs
取締役会の平均在任期間6.8yrs

経営陣の近況

Shareholders May Not Be So Generous With WuXi Biologics (Cayman) Inc.'s (HKG:2269) CEO Compensation And Here's Why

Jun 12
Shareholders May Not Be So Generous With WuXi Biologics (Cayman) Inc.'s (HKG:2269) CEO Compensation And Here's Why

Recent updates

Shareholders May Not Be So Generous With WuXi Biologics (Cayman) Inc.'s (HKG:2269) CEO Compensation And Here's Why

Jun 12
Shareholders May Not Be So Generous With WuXi Biologics (Cayman) Inc.'s (HKG:2269) CEO Compensation And Here's Why

Some Confidence Is Lacking In WuXi Biologics (Cayman) Inc. (HKG:2269) As Shares Slide 25%

Jun 11
Some Confidence Is Lacking In WuXi Biologics (Cayman) Inc. (HKG:2269) As Shares Slide 25%

Some WuXi Biologics (Cayman) Inc. (HKG:2269) Shareholders Look For Exit As Shares Take 25% Pounding

Jun 11
Some WuXi Biologics (Cayman) Inc. (HKG:2269) Shareholders Look For Exit As Shares Take 25% Pounding

Here's Why WuXi Biologics (Cayman) (HKG:2269) Can Manage Its Debt Responsibly

Apr 15
Here's Why WuXi Biologics (Cayman) (HKG:2269) Can Manage Its Debt Responsibly

Why Investors Shouldn't Be Surprised By WuXi Biologics (Cayman) Inc.'s (HKG:2269) 25% Share Price Surge

Mar 04
Why Investors Shouldn't Be Surprised By WuXi Biologics (Cayman) Inc.'s (HKG:2269) 25% Share Price Surge

Things Look Grim For WuXi Biologics (Cayman) Inc. (HKG:2269) After Today's Downgrade

Dec 08
Things Look Grim For WuXi Biologics (Cayman) Inc. (HKG:2269) After Today's Downgrade

Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?

Nov 26
Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?

Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)

Nov 10
Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)

What Does WuXi Biologics (Cayman) Inc.'s (HKG:2269) Share Price Indicate?

Sep 26
What Does WuXi Biologics (Cayman) Inc.'s (HKG:2269) Share Price Indicate?

These 4 Measures Indicate That WuXi Biologics (Cayman) (HKG:2269) Is Using Debt Reasonably Well

Aug 26
These 4 Measures Indicate That WuXi Biologics (Cayman) (HKG:2269) Is Using Debt Reasonably Well

WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Could Be 24% Below Their Intrinsic Value Estimate

Aug 10
WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Could Be 24% Below Their Intrinsic Value Estimate

Is WuXi Biologics (Cayman) Inc. (HKG:2269) Potentially Undervalued?

Jun 19
Is WuXi Biologics (Cayman) Inc. (HKG:2269) Potentially Undervalued?

Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)

May 12
Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)

Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?

Mar 25
Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?

At HK$52.00, Is WuXi Biologics (Cayman) Inc. (HKG:2269) Worth Looking At Closely?

Mar 13
At HK$52.00, Is WuXi Biologics (Cayman) Inc. (HKG:2269) Worth Looking At Closely?

Does WuXi Biologics (Cayman) (HKG:2269) Deserve A Spot On Your Watchlist?

Feb 13
Does WuXi Biologics (Cayman) (HKG:2269) Deserve A Spot On Your Watchlist?

An Intrinsic Calculation For WuXi Biologics (Cayman) Inc. (HKG:2269) Suggests It's 29% Undervalued

Jan 30
An Intrinsic Calculation For WuXi Biologics (Cayman) Inc. (HKG:2269) Suggests It's 29% Undervalued

Is WuXi Biologics (Cayman) (HKG:2269) A Risky Investment?

Dec 09
Is WuXi Biologics (Cayman) (HKG:2269) A Risky Investment?

Why WuXi Biologics (Cayman) Inc. (HKG:2269) Could Be Worth Watching

Nov 20
Why WuXi Biologics (Cayman) Inc. (HKG:2269) Could Be Worth Watching

With EPS Growth And More, WuXi Biologics (Cayman) (HKG:2269) Makes An Interesting Case

Nov 08
With EPS Growth And More, WuXi Biologics (Cayman) (HKG:2269) Makes An Interesting Case

Is WuXi Biologics (Cayman) Inc. (HKG:2269) Trading At A 47% Discount?

Oct 27
Is WuXi Biologics (Cayman) Inc. (HKG:2269) Trading At A 47% Discount?

WuXi Biologics (Cayman) (HKG:2269) Seems To Use Debt Quite Sensibly

Sep 08
WuXi Biologics (Cayman) (HKG:2269) Seems To Use Debt Quite Sensibly

Is Now The Time To Look At Buying WuXi Biologics (Cayman) Inc. (HKG:2269)?

Aug 15
Is Now The Time To Look At Buying WuXi Biologics (Cayman) Inc. (HKG:2269)?

We Ran A Stock Scan For Earnings Growth And WuXi Biologics (Cayman) (HKG:2269) Passed With Ease

Aug 02
We Ran A Stock Scan For Earnings Growth And WuXi Biologics (Cayman) (HKG:2269) Passed With Ease

Estimating The Intrinsic Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)

Jun 29
Estimating The Intrinsic Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)

What Does WuXi Biologics (Cayman) Inc.'s (HKG:2269) Share Price Indicate?

May 16
What Does WuXi Biologics (Cayman) Inc.'s (HKG:2269) Share Price Indicate?

Here's Why I Think WuXi Biologics (Cayman) (HKG:2269) Might Deserve Your Attention Today

May 03
Here's Why I Think WuXi Biologics (Cayman) (HKG:2269) Might Deserve Your Attention Today

CEO報酬分析

WuXi Biologics (Cayman) の収益と比較して、Chris Chen の報酬はどのように変化したか?
日付総報酬給与会社業績
Dec 31 2023CN¥97mCN¥4m

CN¥3b

Sep 30 2023n/an/a

CN¥4b

Jun 30 2023n/an/a

CN¥4b

Mar 31 2023n/an/a

CN¥4b

Dec 31 2022CN¥79mCN¥3m

CN¥4b

Sep 30 2022n/an/a

CN¥4b

Jun 30 2022n/an/a

CN¥4b

Mar 31 2022n/an/a

CN¥4b

Dec 31 2021CN¥51mCN¥3m

CN¥3b

Sep 30 2021n/an/a

CN¥3b

Jun 30 2021n/an/a

CN¥3b

Mar 31 2021n/an/a

CN¥2b

Dec 31 2020CN¥31mCN¥3m

CN¥2b

Sep 30 2020n/an/a

CN¥1b

Jun 30 2020n/an/a

CN¥1b

Mar 31 2020n/an/a

CN¥1b

Dec 31 2019CN¥25mCN¥3m

CN¥1b

Sep 30 2019n/an/a

CN¥922m

Jun 30 2019n/an/a

CN¥831m

Mar 31 2019n/an/a

CN¥731m

Dec 31 2018CN¥20mCN¥2m

CN¥631m

Sep 30 2018n/an/a

CN¥520m

Jun 30 2018n/an/a

CN¥410m

Mar 31 2018n/an/a

CN¥331m

Dec 31 2017CN¥24mCN¥2m

CN¥253m

報酬と市場: Chrisの 総報酬 ($USD 13.37M ) は、 Hong Kong市場 ($USD 899.42K ) の同規模の企業の平均を上回っています。

報酬と収益: Chrisの報酬は 20% 以上増加しましたが、会社の収益は過去 1 年間で 20% 以上減少しました。


CEO(最高経営責任者

Chris Chen (51 yo)

8.4yrs

在職期間

CN¥96,911,000

報酬

Dr. Zhisheng Chen, also known as Chris, Ph.D. has been the Chief Executive Officer & Executive Director at WuXi Biologics (Cayman) Inc. since January 01, 2016 and since February 27, 2014 respectively. Dr....


リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Ge Li
Founder & Chairman10.3yrsデータなしデータなし
Zhisheng Chen
CEO & Executive Director8.4yrsCN¥96.91m0.34%
CN¥ 164.4m
Weichang Zhou
Honorary President of Global Biologics Development9.2yrsCN¥32.89m0.012%
CN¥ 5.6m
Ming Tu
CFO & Executive VP2.6yrsデータなしデータなし
Lihua Yu
COO & Senior VPless than a yearデータなしデータなし
Sherry Gu
Chief Technology Officer and Executive VP of Global Biologics Development Departmentless than a yearデータなしデータなし
Jijie Gu
Chief Scientific Officer & President of Global Biologics Researchno dataデータなしデータなし
Lina Fan
Senior VP & Head of Investor Relationsless than a yearデータなしデータなし
Cong Ding
VP & Head of Legal Departmentno dataデータなしデータなし
He Wang
Chief Compliance Officer1.8yrsデータなしデータなし
Li Xiong
VP & Head of Global Human Resourcesno dataデータなしデータなし
Angus Scott Turner
Senior VP and Head of Global BD & Alliance Managementno dataデータなしデータなし

1.8yrs

平均在職期間

56yo

平均年齢

経験豊富な経営陣: 2269の経営陣は 経験豊富 とはみなされません ( 1.8年の平均在職年数)。これは新しいチームを示唆しています。


取締役

名称ポジション在職期間報酬所有権
Ge Li
Founder & Chairman10.3yrsデータなしデータなし
Zhisheng Chen
CEO & Executive Director10.3yrsCN¥96.91m0.34%
CN¥ 164.4m
Weichang Zhou
Honorary President of Global Biologics Development8.1yrsCN¥32.89m0.012%
CN¥ 5.6m
Jackson Tai
Independent Non-Executive Director1.1yrsCN¥710.00k0.00062%
CN¥ 297.0k
James Larrick
Member of Scientific Advisory Board6.4yrsデータなしデータなし
David D. Ho
Member of Scientific Advisory Board6.4yrsデータなしデータなし
Wei-Shou Hu
Member of Scientific Advisory Board6.4yrsデータなしデータなし
Ram Sasisekharan
Member of Scientific Advisory Board6.4yrsデータなしデータなし
William Robert Keller
Independent Non-Executive Director7.1yrsCN¥906.00k0.00053%
CN¥ 253.9k
Yanling Cao
Non-Executive Director8.1yrsデータなしデータなし
Yibing Wu
Non-Executive Director8.1yrsデータなしデータなし
Kenneth Walton Hitchner
Independent Non-Executive Director4yrsCN¥933.00k0.0049%
CN¥ 2.3m

6.8yrs

平均在職期間

59.5yo

平均年齢

経験豊富なボード: 2269の 取締役会経験豊富 であると考えられます ( 6.8年の平均在任期間)。